Insider · CIK 0001684584
Yun Yen
Files at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). First filing -, latest -.
In brief
Yun Yen files SEC Form 4 as director at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Yun Yen has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Options to Purchase Common Stockderivative | +10,000 | $0.00 | $0 | 10,000 | Jul 9, 2025 |
| Jun 30, 2025 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Options to Purchase Common Stockderivative | +11,632 | $0.00 | $0 | 11,632 | Jul 9, 2025 |
| Mar 31, 2025 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Options to Purchase Common Stockderivative | +8,777 | $0.00 | $0 | 8,777 | Apr 2, 2025 |
| Sep 30, 2024 | NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC. | AGrant or award Options to Purchase Common Stockderivative | +5,786 | $0.00 | $0 | 5,786 | Oct 29, 2024 |
Questions about Yun Yen
Answered from the filings on this page, as of the latest one.
Is Yun Yen buying or selling?
Yun Yen has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Yun Yen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Yun Yen has 0.
Where does Yun Yen file Form 4?
Yun Yen has filed Form 4 at NMAD (LIXTE BIOTECHNOLOGY HOLDINGS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.